Diagnosis and management of right atrial thrombus in heparin-induced thrombocytopenia and thrombosis syndrome with transesophageal echocardiography and thrombolytic therapy

Elliott, Lorrie; Lichtenberg, Robert; Johnson, Sarah A.; Lewis, Bruce E.

doi:10.1016/s0002-8703(96)90104-0

Cited by 8 publications

(2 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Other anticoagulants reported include danaparoid (n = 1), rivaroxaban (n = 1) and fondaparinux (n = 1). One case reported treatment with urokinase in addition to warfarin, 55 and one case reported the use of aspirin alone 57 …”

Section: Resultsmentioning

confidence: 99%

“…Fourteen studies detailed the use of IVIG or TPE as initial therapy (see Table 2). Twelve studies included 13 case reports 46,[48][49][50][51][52][53][54][55][56][57][58] and one case series included four patients. 14 One case-controlled study of 44 patients reported aggregate data on 26 TPE-treated patients and is summarized separately.…”

Section: Treatment Indication 2: Initial Therapymentioning

confidence: 99%

See 1 more Smart Citation

Therapeutic plasma exchange and intravenous immune globulin in the treatment of heparin‐induced thrombocytopenia: A systematic review

et al. 2020

View full text Add to dashboard Cite

Background: Immunomodulatory strategies in heparin-induced thrombocytopenia (HIT) include the use of intravenous immune globulin (IVIG) and therapeutic plasma exchange (TPE). The optimal application of these therapies is unknown and outcomes data are limited. We investigated treatment categories and laboratory and clinical outcomes of IVIG and/or TPE in HIT with a systematic literature review. Study Design and Methods: We searched MEDLINE, Embase, and Web of Science through December 2019 for studies combining controlled vocabulary and keywords related to thrombocytopenia, heparin, TPE, and IVIG. The primary outcome was treatment indication. Secondary outcomes were platelet recovery, HIT laboratory parameters, heparin re-exposure, and post-treatment course. Case-level data were analyzed by qualitative synthesis. Results: After 4241 references were screened, we identified 60 studies with four main categories of IVIG and/or TPE use as follows: (a) treatment of refractory HIT (n = 35; 31%); (b) initial therapy (n = 45; 40%); (c) cardiopulmonary bypass surgery (CPB; n = 30; 27%); and (d) other (n = 2; 2%). IVIG was most commonly used for the treatment of refractory HIT while TPE was primarily used to facilitate heparin exposure during CPB. Both IVIG and TPE were

show abstract

Section: Resultsmentioning

confidence: 99%